Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.17 USD | +0.97% | -8.53% | +151.81% |
May. 07 | HC Wainwright Adjusts Price Target on ADC Therapeutics to $8 From $9, Maintains Buy Rating | MT |
May. 06 | Rate Cut Hopes Lift Exchange-Traded Funds, Equity Futures Pre-Bell Monday | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+151.81% | 397M | |
+7.64% | 113B | |
+10.40% | 106B | |
+0.41% | 22.27B | |
-11.88% | 22.22B | |
-5.99% | 19.43B | |
-37.36% | 17.87B | |
-5.08% | 17.24B | |
+6.52% | 14.29B | |
+36.23% | 12.52B |
- Stock Market
- Equities
- ADCT Stock
- News ADC Therapeutics SA
- ADC Therapeutics Plans to End Phase 2 Trial of Zynlonta, Rituximab in Untreated DLBCL Patients